MAUDE Adverse Event Report: MICROVENTION, INC. LVIS EVO; INTRALUMINAL DEVICES

Model Number LEV2512-MVE

Device Problem Adverse Event Without Identified Device or Use Problem (2993)

Patient Problems Paresis (1998); Speech Disorder (4415); Ischemia Stroke (4418); Thrombosis/Thrombus (4440)

Event Date 06/27/2023

Event Type  Injury  

Event Description

It was reported that a stent was implanted along with embolization coils in (b)(6) 2022, to treat a saccular sidewall aneurysm.On (b)(6), 2023, the patient experienced stroke and presented with aphasia and hemiparesis shortly after they discontinued prasugrel on (b)(6), 2023.Partial medial infarction on the left (mainly in the area of the basal ganglia) and dsa evidence of a central thrombus in the left middle cerebral artery (from the aci-t fork to the proximal trunk in anterior to the mca} was observed.The patient was given aggrastat for 24 hours and then resumed prasugrel along with asa 100mg.The event resolved without sequelae on (b)(6), 2023.

Manufacturer Narrative

A search for non-conformances associated with this part/lot number combination did not reveal any production-related issues relevant to the complaint that occurred during manufacturing of the device.The device was implanted in the patient and not returned to the manufacturer for evaluation.Imaging is being sought but it has not yet been provided for analysis.The event as described could not be confirmed.If imaging or more information is made available at a late date, an investigation will be performed and a supplemental report will be submitted.The instructions for use (ifu) identifies stroke as a potential complication associated with use of the device.

Event Description

It was reported that a stent was implanted along with embolization coils in (b)(6) 2022 to treat a saccular sidewall aneurysm.On (b)(6) 2023, the patient experienced stroke and presented with aphasia and hemiparesis shortly after they discontinued prasugrel on (b)(6) 2023.Partial medial infarction on the left (mainly in the area of the basal ganglia) and dsa evidence of a central thrombus in the left middle cerebral artery (from the aci-t fork to the proximal trunk in anterior to the mca} was observed.The patient was given aggrastat for 24 hours and then resumed prasugrel along with asa 100mg.The event resolved without sequelae on (b)(6) 2023.

Manufacturer Narrative

Items returned: n/a.Visual analysis: a visual inspection of the device captured in this file could not be performed as a physical device was not returned for evaluation.Investigation findings: without the return and physical evaluation of the device, the investigation cannot definitively determine if a condition existed that would have caused or contributed to the reported event.Based on a review of the device¿s risk documentation, the reported event did not indicate there were any potential or new manufacturing, design, quality, or other systemic issues, or non-conformances.The complaint code is monitored through the trending process; corrective action is determined, as needed, through this process.Investigations of historic complaint files with similar complaint category coding are recorded in the complaint handling system; without the ability to perform and analysis of the device, this investigation cannot identify with certainty any potential root causes.Batch review: a search for non-conformances associated with this part/lot number combination did not reveal any production-related issues relevant to the complaint that occurred during manufacturing of the device.Complaint system review: there are no similar complaints based on the complaint category regarding this batch number from the last two years recorded in the complaint system at the time of this investigation.Ifu review (additional information can be found in the ifu): potential complications.Possible complications include but are not limited to the following: hematoma at the puncture site; perforation or dissection of the vessel(s); intravascular spasm; hemorrhaging; rupture or perforation of aneurysm; coil herniation; device migration; neurologic insufficiencies including stroke and death; ischemia; vascular occlusion; vessel stenosis; incomplete aneurysm occlusion; pseudoaneurysm formation; distal embolization; headache; infection; reaction to contrast agents including severe allergic reactions and renal failure.Warnings: should unusual resistance be felt at any time during access or removal, the introducer/guide catheter/microcatheter and lvis evo device should be removed as a single unit.Applying excessive force during delivery or retrieval of the lvis evo device can potentially result in loss or damage to the device and delivery components.It is imperative to use the lvis evo device with compatible microcatheters.If repeated friction is encountered during lvis evo device delivery, verify microcatheter is not kinked or in extremely tortuous anatomy.Confirm that the microcatheter does not ovalize.Confirm that there is adequate sterile flush solution.Do not reposition the lvis evo device in the parent vessel without fully retrieving the device.The lvis evo device must be retrieved into the microcatheter and re-deployed at the desired target location or removed completely from the patient.Precautions exercise caution when crossing the deployed/detached lvis evo device with adjunctive devices such as guidewires, catheters, microcatheters or balloon catheters to avoid disrupting the device geometry and device placement.Directions for use 15.Advance the delivery wire to transfer the lvis evo device from within the introducer into the microcatheter.Warning: do not torque the delivery wire while advancing or retracting the lvis evo device.A torque device should not be used.16.Continue advancing the delivery wire into the microcatheter until the proximal tip of the delivery wire enters the introducer.Loosen the rhv locking ring, remove the introducer, and set it aside.Warning: do not apply undue force.If resistance is encountered at any point during lvis evo device delivery or manipulation, withdraw the unit and select a new lvis evo device.18.Position the lvis evo device for deployment by aligning the lvis evo implant distal radiopaque end markers approximately 7 mm or adequate length past the aneurysm neck.Note: a proper push/pull technique, encompassing sufficient delivery wire push force, in addition to an opposing microcatheter withdrawal force, will facilitate properly deploying the lvis evo device to achieve full expansion and good vessel apposition.Note: slowly advancing the lvis evo device while adjusting the microcatheter position will ensure accurate deployment.Maintain simultaneous control of the lvis evo device and microcatheter in order to position and expand the device at the proper location.Caution: using a rapid microcatheter withdrawal technique to deploy the lvis evo device is not recommended and may result in device elongation.19.If lvis evo device positioning is not satisfactory, the lvis evo device may be recaptured and repositioned if it is not fully deployed.The lvis evo device may be recaptured until the point where the proximal end of the lvis evo device markers is aligned 3 mm proximally with the microcatheter distal marker band.Caution: if resistance is felt while recapturing the lvis evo device, do not continue to recapture the device.Withdraw the microcatheter slightly to unsheath the lvis evo device (without exceeding the recapture limit), and then attempt to recapture the lvis evo device.Caution: the lvis evo device must not be re-deployed more than three times.Note: the lvis evo device delivery wire should not be utilized as a guidewire.Do not torque the lvis evo device.A torque device should not be used.20.If lvis evo device positioning is satisfactory, carefully retract the microcatheter and advance the delivery wire together, to allow the lvis evo device to deploy across the neck of the aneurysm.Ensure the device proximal radiopaque end markers are approximately 7 mm or adequate length proximal to the aneurysm neck to ensure an adequate landing zone.The lvis evo device will expand and total length may foreshorten up to 60% from its undeployed length as it exits the microcatheter.Ensure microcatheter is retracted and clear from the proximal flared ends.Note: visualize and refer to the implant radiopaque end markers to maintain adequate implant length, approximately 7 mm or adequate length on each side of the aneurysm neck or target location to ensure appropriate neck coverage.Warning: do not detach the lvis evo device if it is not properly positioned in the parent vessel.Observe the delivery wire distal tip to assure it remains within the desired location of the parent vessel.21.Prior to removing the delivery wire and if necessary, carefully position the microcatheter distal to the lvis evo device to maintain access through the lvis evo device.Remove and discard the delivery wire.Warning: the lvis evo device delivery wire should not be utilized as a guidewire.Do not torque the lvis evo device.A torque device should not be used.23.Use the guidewire and microcatheter to access the aneurysm through the lvis evo device cells.Warning: observe lvis evo device marker position during placement of the microcatheter into the aneurysm to ensure that the lvis evo device does not migrate or dislodge from its deployed position.Note: access to the aneurysm may be facilitated by the use of a microcatheter that has been shaped.25.Warning: observe lvis evo device marker position during the coiling procedure to ensure that the device does not migrate from its deployed position.After placing the last coil, verify that the lvis evo device has remained patent and properly positioned.Advance a guidewire, if necessary, to the microcatheter tip and carefully remove the microcatheter.Note: a microcatheter may be positioned into the aneurysm sac prior to delivery of the lvis evo device.The microcatheter will be supported by the lvis evo device during delivery of embolic coiling.After completing the coiling, the coiling microcatheter should be carefully removed to avoid dislodging the lvis evo device.27.Caution: carefully watch the lvis evo device distal and proximal markers when passing through the deployed lvis evo device with embolic coiling microcatheters to avoid displacing the lvis evo device.Procedure/medical information review: imaging review: a 310 mb dicom file is supplied.It contains ap and lateral subtracted dsa angiograms (with contrast) of the left ica, an ap dsa of the right common femoral artery and an ap chest x-ray.Left ica dsa, 12h08: right ica dsa, ap & lateral.Lvis evo is faintly seen (because this is a subtracted run) from mid supraclinoid ica to proximal inferior m2 division of m1 mca.There is a dense coil pack in an approximately 5 x 8 mm ica terminus/proximal dorsal wall m1 aneurysm (no measurements provided); no contrast enters aneurysm.There is a mild amount of clot at the coil/stent interface, and possibly a slight amount of clot at the ostium of the jailed m2 superior division.No distal emboli.Left ica dsa, 12h09: right ica dsa, ap & lateral, magnified view.The above-described findings are better seen.Left ica dsa, 12h11: right ica dsa, ap & lateral, magnified view.About the same as at 12h09.Left ica dsa, 12h12: right ica dsa, ap & lateral, magnified view.The previously described clot is barely perceptible.Right common femoral dsa through arterial sheath, 12h44: normal appearing right cfa.Ap chest x-ray, 12h48: normal chest x-ray.An endotracheal tube is seen with its tip at the level of the third rib, well above the carina.These images confirm the presence of the clot, but do not explain why the clot described in the complaint occurred.Without the return and physical evaluation of the device, the investigation is unable to determine if a condition existed that would have caused or contributed to the reported event.Procedure note-medical note review: a detailed procedure note-medical note review has been performed for complaint.Data review indicates the patient received therapy for a partial medial infarction on the left (mainly in the area of the basal ganglia) with existing mild hemiparesis on the right side.Further clinical data review indicates evidence of a central thrombus in the left middle cerebral artery (from the aci-t fork to the proximal trunk in anterior to the mca} with properly inserted stents and complete coil embolization of the broad-based media aneurysm reported.Procedure note medical note review conclusion for complaint (b)(4): a detailed procedure note-medical note review has been performed and completed for complaint (b)(4).Data review indicates that there is no report of stent device malfunction associated with this procedure.In addition, there is no reported coil device malfunction reported for this procedure.Data review further confirms properly inserted stents and completed coil embolization which was confirmed thru the performance of digital subtraction angiography.

• Brand Name: LVIS EVO
• Type of Device: INTRALUMINAL DEVICES
• Manufacturer (Section D): MICROVENTION, INC.; 35 enterprise; aliso viejo CA 92656
• Manufacturer Contact: terrence callahan ; 35 enterprise; aliso viejo, CA 92656 ; 7142478000
• MDR Report Key: 17815108
• MDR Text Key: 324222403
• Report Number: 2032493-2023-00957
• Device Sequence Number: 1
• Product Code: QCA
• UDI-Device Identifier: 00842429103425
• UDI-Public: (01)00842429103425(11)220808(17)250731(10)0000239683
• Combination Product (y/n): N
• Reporter Country Code: US
• PMA/PMN Number: P170013
• Number of Events Reported: 1
• Summary Report (Y/N): N
• Report Source: Manufacturer
• Source Type: Foreign,Health Professional,User Facility,Company Representative
• Reporter Occupation: Physician
• Type of Report: Initial,Followup
• Report Date: 11/29/2023

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Is this an Adverse Event Report?: Yes
• Is this a Product Problem Report?: No
• Device Operator: Health Professional
• Device Model Number: LEV2512-MVE
• Device Lot Number: 0000239683
• Was Device Available for Evaluation?: No
• Is the Reporter a Health Professional?: Yes
• Was the Report Sent to FDA?: No
• Initial Date Manufacturer Received: 09/08/2023
• Initial Date FDA Received: 09/26/2023
• Supplement Dates Manufacturer Received: 11/09/2023
• Supplement Dates FDA Received: 11/29/2023
• Was Device Evaluated by Manufacturer?: Device Not Returned to Manufacturer
• Date Device Manufactured: 08/08/2023
• Is the Device Single Use?: Yes
• Is This a Reprocessed and Reused Single-Use Device?: No
• Type of Device Usage: Initial
• Patient Sequence Number: 1
• Patient Outcome(s): Required Intervention
• Patient Age: 25 YR
• Patient Sex: Female